SOVREMENNAYA PEDIATRIYA.2016.4(76):78-83; doi10.15574/SP.2016.76.78 

Features ofliver fibrosis in children with chronic viral hepatitis B and different variants of gene polymorphism of IL-28B 

Berezenko V. S., Tsaryova O. V., Dyba M. B.

SI «InstituteofPediatrics, ObstetricsandGynecologyof NAMS ofUkraine», Kyiv, Ukraine

RegionalHospital of InfectiousDiseases, Zaporizhzhya, Ukraine 

Purpose. To study the features of liver fibrosis in children with chronic hepatitis B (CHB) depending on the variant of the gene polymorphism of IL-28B.

Materials and methods.The study involved 66 children aged 3–18 years with chronic hepatitis B. All patients were involved in clinical, laboratory and instrumental examination. The stage of fibrosis was assessed morphologicallyon a scale METAVIR, by the calculation method — Fibro Test, on APRI index, and by the concentration of hyaluronic acid (HA), transforming growth factor TGF-β1 in serum usingIFA. The SNP genotypes of rs8099917 and rs12979860 lociin IL-28B were determinedby the method of the polymer chain reaction (PCR). A statistical analysis of the datawas conducted.

Results. Most of the patients had genotype CC at rs12979860 locus of the gene IL-28B (31.5%) and the TT genotype at rs8099917 locus (41.6%).It was found that fibrogenesis in the liver of patients with chronic hepatitis B depends on the polymorphism of the gene IL-28B. The worst scenario for the development of liver fibrosis and the formation of HBeAg negative hepatitis B in children is a CT genotype (rs12979860). Variants CC (rs12979860) and TT (rs8099917) have a beneficial effect on fibrogenesis in the liver in this group of patients.

Conclusions.The polymorphism variants CC (rs12979860) and TT (rs8099917)of the gene IL-28B are more favorable (lower severity of fibrosis) in the progression of chronic hepatitis B in children. HBeAg negative hepatitis B in children often occurs in patients with a CT polymorphism (rs12979860) and is characterized by a significant fibrotic changes in the liver.

Key words: children, chronic viral hepatitis B, gene polymorphism of IL-28B, liver fibrosis, hyaluronic acid, transforming growth factor TGF-β1.

REFERENCES

1. Abdurahmanov DT. 2010. Chronic hepatitis B and D. Moscow, GEOTAR-Media: 288.

2. Ivashkin VT. 2005. Diseases of the liver and biliary tract. A guide for physicians. 2nd ed. Moscow: 536.

3. Lopatkina TN, Kudlinskiy IS. 2011. The role of interleukin 28B gene polymorphism in the evaluation of the effectiveness of antiviral therapy for chronic hepatitis C. Clinical Hepatology. 2: 28—38.

4. Surkov AN. 2009. Serum markers of fibrosis in chronic liver diseases in children. Thesis abstract … PhD: 14.00.09. Scientific Center of Children’s Health. Moscow: 25.

5. Filimonov P.N, Gavrilov NI, Shkurupiy VA. 2004. The probability of development of liver fibrosis in children with viral hepatitis. N: 17—26.

6. Chuelov SB. 2010. Liver cirrhosis of infectious nature in children. Thesis abstract … MD: 14.00.30. GOU VPO «Russian State Medical University». Moscow: 48.

7. Wai CT, Greenson JK, Fontana RJ et al. 2003. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis. Hepatology. 38(2): 518—526. http://dx.doi.org/10.1053/jhep.2003.50346; PMid:12883497

8. Ferreira SG, Chacha SG, Souza FF et al. 2015. Association between IL28B polymorphisms and spontaneous HBsAg seroconversion in patients with chronic hepatitis B virus (HBV) infection. Ueg week. Poster session. 28.10.2015. 9.00—17.00.

9. Bochud PY, Bibert S, Kutalic Z et al. 2012. Il28b alleles associated with poor Hepatitis C virus (hcv) clearance protect against inflammation and fibrosis in patients infected with non-1 hcv genotypes. Hepatology. 55: 384—394. http://dx.doi.org/10.1002/hep.24678; PMid:22180014

10. Chang M, Hsu H, Ni Y et al. 1995. The significance of spontaneous hepatitis B e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen before 3 years of age. Hepatology. 22: 1387—1392. http://dx.doi.org/10.1002/hep.1840220508; http://dx.doi.org/10.1016/0270-9139(95)90141-8

11. Kandemir O, Fidanci SB, Demir N et al. 2013. Chronic hepatitis B and IL28B rs12979860 polymorphism: preliminary study. Mol Biol Rep. 40(11): 6189—6194. http://dx.doi.org/10.1007/s11033-013-2730-0; PMid:24057245

12. D'Ambrosio R, Aghemo A, De Francesco R et al. 2014. The association of il28b genotype with the histological features of chronic hepatitis C is HCV genotype dependent. Int J Mol Sci. 15(5): 7213—7224. http://dx.doi.org/10.3390/ijms15057213; PMid:24776764 PMCid:PMC4057668

13. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009. 50: 227—242. http://dx.doi.org/10.1016/j.jhep.2008.10.001; PMid:19054588

14. Fabris C, Falleti E, Cussigh A et al. 2011. Fabris C. IL-28B rs 12979860 C/T allele distribution in patients with liver cirrhosis role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 54(4): 716—722. http://dx.doi.org/10.1016/j.jhep.2010.07.019; PMid:21146242

15. Ge D, Fellay J, Thompson AJ et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 46: 399—401. http://dx.doi.org/10.1038/nature08309; PMid:19684573

16. Seto WK, Wong DK, Kopaniszen M et al. 2013. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis. 56: 1695—1703. http://dx.doi.org/10.1093/cid/cit121; PMid:23449268

17. Peng LJ, Guo JS, Zhang Z et al. 2012. IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. Tissue Antigens. 79: 302—305. http://dx.doi.org/10.1111/j.1399-0039.2011.01835.x; PMid:22239156

18. Martin MP, Qi Y, Goedert JJ et al. 2010. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. The Journal of infectious diseases. 202: 1749—1753. http://dx.doi.org/10.1086/657146; PMid:20977343 PMCid:PMC2974014

19. Agundez JA, Garcia-Martin E, Maestro ML et al. 2012. Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS One. 7(5): e37998. http://dx.doi.org/10.1371/journal.pone.0037998; PMid:22666430 PMCid:PMC3362530

20. Sonneveld MJ, Wong VW, Woltman AM et al. 2012. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology. 142: 513—520. http://dx.doi.org/10.1053/j.gastro.2011.11.025; PMid:22108195

21. Suppiah V, Moldovan M, Ahlenstiel G et al. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 41(10): 1100—1104. http://dx.doi.org/10.1038/ng.447; PMid:19749758

22. Rauch A, Kutalik Z, Descombes P et al. 2010. Swiss HIV Cohort study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 138(4): 1338—1347. http://dx.doi.org/10.1053/j.gastro.2009.12.056; PMid:20060832

23. Tanaka Y, Nishida N, Sugiyam M et al. 2009. Genome-wide association of IL28D with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 41(10): 1105—1109. http://dx.doi.org/10.1038/ng.449; PMid:19749757

24. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Guidelines. 2015, March: 15—17.